ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
 PMID: 29630974       2018       Antiviral research
Abstract: 3.69-fold in half maximal effective concentration of wild-type strain); rtA181T/sW172L + rtS202G + rtM204V strain exhibited higher HBV DNA production and entecavir resistance fold than that of rtA181T/sW172* + rtS202G + rtM204V strain (50.98% vs.
Abstract: 44.33% (524/1182) rtA181T-positive samples were detected with signature drug-resistant mutations,


  Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
 PMID: 29654894       2018       International journal of antimicrobial agents
Abstract: Despite >50% of M204I/V+-L180M among all HBV resistance cases annually and extensive exposure of patients to lamivudine (LAM), telbivudine (LdT) and adefovir dipivoxil (ADV), ETV resistance also showed a dramatically increased incidence, which rose to 17.1% in 2016.


  [Monitoring by high-sensitivity HBV DNA assay during treatment in chronic hepatitis B e antigen negative patients].
 PMID: 29804376       2018       Zhonghua gan zang bing za zhi
Abstract: New mutation sites such as G1915A / C, L180M, M204V, V207I / L, T184A and V173L were detected, Low resistance rate (25%).


  Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.
 PMID: 29859062       2018       BMC infectious diseases
Abstract: Strong correlation was observed between sP120T and rtM204I/V (P < 0.001), and their co-presence determined an increased HBV-DNA.
Abstract: The immune-associated escape mutations and the NA-induced immune-escape mutations sI195M, sI196S, and sE164D (resulting from drug-resistance mutation rtM204 V, rtM204I, and rtV173L) were retrieved from literature and examined.
Figure: The NA-induced immune-escape mutations


  Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient.
 PMID: 30075160       2018       Virus research
Abstract: Sequencing reverse transcriptase region of HBV revealed that the patient developed lamivudine-resistant mutations (rtV173 L, rtL180 M, and rtM204 V) 36 months after the start of lamivudine therapy, and lamivudine-resistant mutants reversed to wild-type after the treatment was stopped for 8 months.


  A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action.
 PMID: 30080852       2018       PLoS neglected tropical diseases
Abstract: The commonest RAM was rtM204I/V, either alone or in combination with associated mutations, and identified in both reportedly treatment-naive and treatment-experienced adults.
Abstract: We also identified the suite of mutations rtM204V/I + rtL180M + rtV173L, that has been associated with vaccine escape, in over 1/3 of cohorts.
Result: In addition to South Africa, rtM204I/V was also frequent in Malawi among treatment experienced patients (n = 24/154, 16%) (Fig 3), and in genotype non-A infection: in this setting, the mutation was detected in genotype C infection (n = 2/17, 12%) (S2 Fig).


  Genetic variability in coding regions of the surface antigen and reverse transcriptase domain of hepatitis B virus polymerase, Colombia, 2002-2014
 PMID: 30184362       2018       Biomedica
Abstract: The L180M and M204V resistance mutations were simultaneously identified in one sample, while the I169L resistance mutation was identified in another one.


  Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis.
 PMID: 30202825       2018       Hepatology communications
Abstract: HBV harboring the rtA181C substitution without LVDr substitutions rtL180M+rtM204V remained susceptible to inhibition by ETV, adefovir, and tenofovir, although cross-resistance to LVD and telbivudine was observed.
Abstract: One LVD-experienced patient-derived HBV RT harboring LVDr substitutions rtL180M+rtM204V with rtA181C displayed reduced ETV susceptibility (122-fold greater than wild-type HBV) and remained susceptible to adefovir and tenofovir.
Discussion: Cross-resistance occurred between ETV and other approved ant


  Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model.
 PMID: 30586543       2018       The Brazilian journal of infectious diseases
1Abstract: We generated a stable cell line encoding the major pattern of lamivudine-resistant mutations rtL180M/M204V and designated it ""HepG2.RL1""."


  Occult hepatitis B virus infection in HIV positive patients at a tertiary healthcare unit in eastern India.
 PMID: 28591184       2017       PloS one
Result: Despite the patient population being ART-naive, one OBI sample (O-EICIS.9; belonging to HBV/A1) of 17 (5.9%) harbored the rtL180M+rtM204V lamivudine resistant mutations.
Table: M204V
Discussion: Furthermore, 3TC resistance mutations (rtL180M + rtM204V) were also observed in one of the OBI patients, despite the population being treatment-naive.



Browser Board

 Co-occurred Entities




   Filtrator